Azilect

Azilect can treat early-stage Parkinson’s disease, which affects 10 million people worldwide. Developed by Technion professors Moussa Youdim and John Finberg, in association with Teva Pharmaceuticals, the drug is prescribed in more than 50 countries and is used to treat symptoms including stiffness, tremors, spasms and poor muscle control.